Faecal calprotectin (FCP) is a non-invasive biomarker of intestinal inflammation, levels of which are reported to be elevated in individuals with increased body mass index (BMI). We investigated whether weight loss (WL), induced by dietary and behavioural change in a community weight loss programme (Slimming World), was associated with a reduction in FCP in a longitudinal cohort study. We obtained paired stool samples at the start and 11 --15 6 recently reported that 10% WL over a mean of 46.5 days, using a very low calorie diet in an in-patient setting, was associated with a reduction in rectal mucosal proinflammatory gene expression in 10 individuals. However, the generalisability of short-term changes in mucosal gene expression during a very low calorie diet remains unclear. The relationship between EBW and WL secondary to behavioural modification on colorectal mucosal inflammation, measured using a non-invasive inflammation biomarker, has not been studied previously.
Obesity is associated with a state of chronic systemic inflammation, 1 serum biomarkers of which are reduced by weight loss (WL) associated with bariatric surgery or behavioural (dietary and/or physical activity) modification. 2, 3 Despite the established link between excess body weight (EBW) and increased risk of colorectal cancer, 4 as well as the recognised association between chronic mucosal inflammation and colorectal carcinogenesis in humans, 5 it remains unclear whether EBW and subsequent WL are associated with changes in the degree of colorectal mucosal inflammation. Pendyala et al. 6 recently reported that 10% WL over a mean of 46.5 days, using a very low calorie diet in an in-patient setting, was associated with a reduction in rectal mucosal proinflammatory gene expression in 10 individuals. However, the generalisability of short-term changes in mucosal gene expression during a very low calorie diet remains unclear. The relationship between EBW and WL secondary to behavioural modification on colorectal mucosal inflammation, measured using a non-invasive inflammation biomarker, has not been studied previously.
Calprotectin, a 36-kDa calcium-binding protein derived from activated leukocytes, is present in faeces at a six-fold higher concentration than plasma. 7 Faecal calprotectin (FCP) is a noninvasive biomarker of intestinal inflammation that is used in clinical practice to determine whether further investigation is required to investigate for inflammatory bowel disease (IBD). 8 A primary care study of 'normal' middle-aged individuals has reported a positive correlation between FCP levels and increasing body mass index (BMI), a relationship that was attenuated by controlling for the serum C-reactive protein level. 9 We tested the hypotheses that FCP levels are elevated above the accepted normal range in individuals with EBW and that modest WL achieved during a community WL programme is associated with a reduction in FCP levels.
Approval was obtained from the Leeds (East) Research Ethics Committee. Slimming World (SW) is a commercial weight loss organisation, providing weekly group support sessions facilitating behaviour change in dietary and physical activity levels to promote WL. 10 Potential participants were identified when they first enrolled at SW and were given study information. Written, informed consent was obtained at the next SW visit. New SW members were eligible if they had a BMI X25 kg m À2 and were able to give written informed consent. An individual was ineligible if there was a history of colorectal cancer or colorectal polyp(s), previous colonic surgery for any reason, IBD or coeliac disease, other chronic systemic inflammatory conditions such as rheumatoid arthritis, renal failure, or regular (X4 doses per week) use of non-steroidal anti-inflammatory drugs (NSAIDs).
Participants provided a drug history and data on smoking and alcohol consumption. Symptoms of recent infection were noted, as was recent antibiotic treatment. Height, weight, waist and hip circumference (http://www.nhlbi.nih.gov/guidelines/ obesity/prctgd_c.pdf and http://www.cdc.gov/nchs/data/nhanes/ nhanes3/cdrom/nchs/manuals/anthro.pdf) were recorded by one person (RF). The same measurements were made at the scheduled SW session 11 --15 weeks after enrolment by RF. WL was expressed as the % WL from initial weight or % excess WL.
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A stool sample was obtained at the start and the end of the study period. FCP is stable at room temperature for approximately 1 week, which facilitates sample collection by post. The FCP level in a 'spot' sample accurately predicts the 24-h collection value. 7 A stool sample was obtained at home by participants in a stool sample container and posted to the laboratory using a Biological Substance: Category B container (Royal Mail, UK). Samples were then stored at À80 1C until assay using the PhiCal immunoassay (Calpro AS, Oslo, Norway). Paired samples from the same subject before and after WL were tested in the same assay run. The mean inter-assay coefficient of variation was 14.7% (4 replicates from 3 samples). The FCP level was expressed as mg g À1 faeces. Between January and December 2010, 450 new SW members joined at five study sites in Leeds. Ninety individuals gave consent and were enrolled a median of 1 (range 1 --2) week later. Eight subjects failed to return stool samples. Thirty-nine members left SW o10 weeks after recruitment. Three individuals lost weight and had a BMI o25 kg m À2 at enrolment and so were not followed up.
The 40 evaluable subjects (all Caucasian origin) ranged in BMI between 25.5 and 56.9 kg m À2 (10 overweight, 18 Class I obese and 12 Class II obese). Stool samples were obtained at a median of The time between the last known dose of NSAID used and collection of the stool sample.
FCP levels and weight loss P Kant et al 4 (inter-quartile range (IQR) 2 --6) days after recruitment and at a median of 12 (range 11 --15) weeks later. All subjects lost weight during the study period. There was a mean 6.4±0.5% (s.e.m.) WL (Po0.001, Wilcoxon signed-rank test). Fifteen subjects had o5% WL, whereas 20 had %WL of 5 --10 and 5 had WL 410%. There was a significant reduction in waist circumference (median 95 (IQR 88 --111) to 89 (82 --102) cm; Po0.001, Wilcoxon signed-rank test). There was no significant change in waist --hip ratio (data not shown).
The baseline level of FCP varied between 1.25 and 225 mg g À1 . There was no significant correlation between FCP and individual baseline BMI (Spearman's r ¼ 0.15, P ¼ 0.37). Age, smoking status, alcohol use or NSAID use did not predict the initial FCP level (data not shown). A FCP level of 50 mg g À1 is accepted as the upper limit of the normal adult range for exclusion of IBD. 8 However, despite no history or symptoms suggestive of IBD, 8 (20%) subjects had a baseline FCP value 450 mg g À1 (termed FCP high Figure 1 ). Individual changes in the FCP level during the study period are described in Figure 1 . Considering the study group as a whole, there was no significant difference in FCP level between the start and end of the study period (median (IQR) FCP level 14.4 (5.9 --40.0) mg g À1 versus 12.5 (5.8 --29.4) mg g À1 , respectively. The median (IQR) individual fold change in FCP level during the study was þ 6.5 (À60.6 to þ 55.4). Next, we analyzed data from FCP high and FCP normal individuals independently. Both groups had an equivalent degree of WL (Table 1) . However, there was a difference in the response to WL in the two groups with a onethird-fold reduction in FCP observed in the FCP high group (Table 1  and Figure 1) , a difference from the FCP normal group, which just failed to reach statistical significance (P ¼ 0.065). By contrast, there was no change in FCP level demonstrated in the FCP normal group (Table 1 and Figure 1 ). There was no significant correlation between the individual fold change in FCP and %WL (Spearman's r ¼ À0.25, P ¼ 0.12). Age was the only factor that differed significantly between the two FCP groups (Table 1) . This is the first study to explore the relationship between EBW, WL related to behavioural change and colorectal mucosal inflammation measured by the non-invasive biomarker FCP. We conclude that there is a sub-group (20%) of individuals with EBW, who may have sub-clinical colorectal mucosal inflammation (defined as FCP 450 mg g À1 ), a similar proportion to that observed by Poullis et al. 9 in a primary-care study. The fold decrease in FCP in the FCP high group after WL just failed to reach statistical significance compared with individuals with a normal baseline FCP level, possibly due to type II error and the modest overall %WL. Our data from individuals with a range of EBW are consistent with recent reports of elevated plasma calprotectin (PCP) in obese subjects 12 and a reduction in PCP level after bariatric surgery.
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Unfortunately, we were only able to collect blood from one FCP high individual owing to unacceptability of venepuncture in a community setting. Therefore, we could not investigate whether FCP high individuals had evidence of simultaneous chronic systemic inflammation. A larger cohort study in secondary care will be necessary to explore this relationship. A longer duration prospective study could also investigate an association between baseline FCP level and future risk of colorectal neoplasia, given that persistent elevation of FCP is recognised in patients with colorectal adenoma and cancer. 15 We recognise several methodological limitations inherent to our community-based study. First, we could not completely exclude 'silent' alternative causes of a raised FCP level, including colorectal neoplasia, peptic ulceration and diverticular disease 16 Second, a consequence of our protocol, which gave sufficient time for informed consent, was that participants had already begun to lose weight before collection of the baseline-stool sample. Thirty-six out of forty subjects lost weight (0.2 --6.6 kg; mean %WL 2.1 ± 0.2%) between SW registration and consent at a subsequent meeting (range 7 --21 days; 7 days for 33/40 subjects). Therefore, the baseline FCP data could be confounded by effects of active WL. Third, we accept that our definition of FCP high was based on the use of the FCP assay in a different clinical scenario. 8 A careful correlation between FCP and mucosal biomarkers of inflammation will be required in order to determine the biological significance of FCP levels in EBW.
In conclusion, a subgroup (20%) of asymptomatic individuals with EBW has a raised FCP level indicative of possible subclinical colorectal inflammation. WL prompted by dietary and behavioural change in a community setting may reduce the FCP level in FCP high individuals. A larger cohort study is now warranted in order to determine the exact prevalence of elevated FCP associated with EBW, the link with systemic inflammation and the consequences for future colorectal neoplastic risk.
